AstraZeneca to Present Infectious Disease Protection Data at ECCMID

AstraZeneca will present new clinical and real-world data on its infectious disease protection portfolio at the 34th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Barcelona from April 27-30, 2024. The company is scheduled to present 19 abstracts, including four oral and four late-breaking presentations.

The data focus on protection against respiratory infections and COVID-19. Notably, real-world evidence on the effectiveness of Beyfortus (nirsevimab), a long-acting antibody, in preventing hospitalizations due to respiratory syncytial virus (RSV) in infants and young children will be highlighted. This reinforces the antibody's role in reducing the burden of RSV.

Additionally, AstraZeneca will present updated real-world evidence demonstrating the continued significant burden of COVID-19 in immunocompromised individuals. These findings suggest an ongoing elevated risk for severe COVID-19 outcomes in this population despite multiple vaccinations. The company will also share pharmacokinetic and safety data for sipavibart, an investigational long-acting antibody aimed at preventing COVID-19 in immunocompromised patients.

Early-stage pipeline research will also be showcased, including presentations on a novel mRNA-VLP vaccine platform and a monoclonal antibody targeting recurrent Clostridioides difficile infections. The presentations underscore the ongoing scientific effort to develop new preventative measures against common infectious diseases and their severe manifestations.